5.82 0.82 (16.4%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 6.83 ![]() |
1-year : | 7.98 ![]() |
Resists | First : | 5.84 ![]() |
Second : | 6.83 ![]() |
Pivot price | 4.46 ![]() |
|||
Supports | First : | 3.87 ![]() |
Second : | 2.65 |
MAs | MA(5) : | 5 ![]() |
MA(20) : | 4.31 ![]() |
MA(100) : | 3.63 ![]() |
MA(250) : | 4.12 ![]() |
|
MACD | MACD : | 0.5 ![]() |
Signal : | 0.3 ![]() |
%K %D | K(14,3) : | 97.3 ![]() |
D(3) : | 93.8 ![]() |
RSI | RSI(14): 76.4 ![]() |
|||
52-week | High : | 6.71 | Low : | 2.45 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ABSI ] has closed above the upper band by 6.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 83% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 5.85 - 5.87 | 5.87 - 5.89 |
Low: | 4.98 - 5 | 5 - 5.02 |
Close: | 5.78 - 5.81 | 5.81 - 5.85 |
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Sun, 16 Feb 2025
Needham initiates Absci shares with Buy rating on strategy - MSN
Sun, 16 Feb 2025
Absci (NASDAQ:ABSI) Trading Up 6.8% - What's Next? - MarketBeat
Sun, 16 Feb 2025
Absci Co. (NASDAQ:ABSI) Short Interest Down 10.8% in January - MarketBeat
Wed, 12 Feb 2025
Is Absci Corp. (ABSI) the Best Nasdaq Stock Under $5 to Buy? - Insider Monkey
Fri, 24 Jan 2025
Absci Corporation (ABSI): Pioneering AI-Driven Antibody Discovery with a ‘Buy’ Rating from Needham - Yahoo Finance
Wed, 22 Jan 2025
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 115 (M) |
Held by Insiders | 8.594e+007 (%) |
Held by Institutions | 20 (%) |
Shares Short | 14,020 (K) |
Shares Short P.Month | 0 (K) |
EPS | -8.971e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -1 % |
Return on Assets (ttm) | 698.7 % |
Return on Equity (ttm) | -27.4 % |
Qtrly Rev. Growth | 4.21e+006 % |
Gross Profit (p.s.) | 58.72 |
Sales Per Share | -22.43 |
EBITDA (p.s.) | -2.07854e+007 |
Qtrly Earnings Growth | -1 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -70 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.26 |
Price to Cash Flow | 7.24 |
Dividend | 0 |
Forward Dividend | 2.124e+007 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |